A phase 1b, safety, PK, and efficacy, multicenter, dose-escalating study of imprime PGG in combination with cetuximab/irinotecan therapy in patients with and without recurrent/progressive colorectal carcinoma following treatment with a 5-FU regimen

Trial Profile

A phase 1b, safety, PK, and efficacy, multicenter, dose-escalating study of imprime PGG in combination with cetuximab/irinotecan therapy in patients with and without recurrent/progressive colorectal carcinoma following treatment with a 5-FU regimen

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2010

At a glance

  • Drugs Cetuximab; Irinotecan; PGG-glucan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Biothera
  • Most Recent Events

    • 13 Oct 2010 Final results have been presented at the 35th European Society for Medical Oncology (ESMO) Congress, according to a Biothera media release. Results from both study arms, plus a retrospective analysis, were also reported in the media release.
    • 07 Jul 2010 Results presented at the World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology and also in media release from Biothera.
    • 02 Apr 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top